Latest Announcements

Redington Ltd reported Q2 FY27 revenue of ₹43,002 crore, a 48% year-on-year growth, with PAT excluding exceptional items increasing 50% to ₹581 crore. India revenue grew 67% year-on-year, driven by enterprise technology and data centre investments, while Middle East and Africa revenue increased 41% year-on-year, supported by demand for enterprise infrastructure, cloud and cybersecurity solutions.

Redington Limited has announced its Q2 FY27 financial results, with revenue rising 48% to ₹43,002 crore, and PAT excluding exceptional items growing 50% to ₹581 crore.

NLC India Ltd's board meeting outcome and interim dividend declaration. The company has approved its un-audited financial results for the quarter and half-year ended September 30, 2026, and declared an interim dividend of 15% (Rs. 1.5 per equity share). Additionally, the board has approved a fund-raising plan through the issuance of bonds in the nature of debentures up to Rs. 2,500 Crore in a phased manner. Other resolutions include the setting up of an additional 660 MW unit as an expansion project and the offer for sale of up to 10,00,00,000 equity shares of NLC India Renewables Limited.

Redington Ltd has announced its Q2 & H1 FY 2026-27 earnings, with highest ever revenue and PAT achieved in any quarter. The company has reported strong growth across various business units, with India demonstrating exceptional revenue and PAT growth momentum. However, the Arena business has reported a decline in revenue due to exit from Turkish Lira denominated businesses, resulting in a loss in the quarter.

Redington Limited has announced its Q2 and H1 FY 2026-27 earnings, with the company reporting highest ever revenue and PAT in any quarter. The company has also reported strong growth in its SISA and ROW businesses, with revenue growth of 66% and 27% respectively. However, the company's Arena business has reported a decline in revenue due to exit from Turkish Lira denominated businesses.

ArisInfra Solutions Ltd has announced its unaudited financial results for Q2 and H1 FY27, showing a 28% YoY revenue growth, 220 bps YoY increase in EBITDA margin, and 50% YoY increase in PAT. The company has also provided a guidance for FY27, expecting a 110% YoY increase in PAT.

Meghmani Organics Ltd has announced its unaudited financial results for Q2 FY27, with a standalone net profit of ₹4,532.16 crore and a consolidated net profit of ₹4,292.33 crore.

Ndr Auto Components Limited has informed the Exchange about Investor Presentation on the Financial Results for the quarter and six months ended 30th September 2026.

Marksans Pharma Ltd reported Q2FY27 financial results, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore. H1FY27 revenue grew 32.9% to ₹1,781 crore, and PAT nearly doubled to ₹303 crore.

NDR Auto Components Ltd has announced its Q2 and H1FY27 financial results, showing strong growth across key financial metrics. The company's total income, EBITDA, and PAT have increased by 11.2%, 11.1%, and 7.4% respectively on a year-over-year basis. The company has also expanded its order book and capacity, and has entered into a joint venture with DYA, a leading seat supplier to Hyundai & Kia in Korea.

Marksans Pharma Limited has reported its unaudited financial results for the quarter and half year ended September 30, 2026, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore.

Rajshree Polypack Limited has announced its Q2 and H1 FY2027 financial results, with revenue from operations at ₹102.90 Crores and ₹205.81 Crores respectively, and operating EBITDA at ₹13.05 Crores and ₹27.47 Crores respectively. The company has maintained its operating margins despite a sharp rise in raw material prices and softer export demand. The results also highlight the resilience of the business, with a strong domestic revenue growth of 37.37% YoY in Q2 and a growth of 21.82% YoY in H1.

Marksans Pharma Ltd has announced its Q2FY27 financial results, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore.

Exide Industries Ltd reported H1 FY27 revenue growth of 18.9% and PAT growth of 46.7%, with a strong Q2 performance driven by healthy demand and cost optimisation initiatives.

Marksans Pharma Limited has informed the Exchange about Investor Presentation for Q2FY27, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore.

Exide Industries Limited has reported a 18.9% YoY growth in revenue and 46.7% YoY growth in PAT for H1 FY27, with a strong Q2 performance driven by healthy demand and cost optimisation initiatives.

Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter and half year ended September 30, 2026, along with the declaration of a 2nd interim dividend of INR 5 per equity share. The company has also appointed Ms. Vasuta Agarwal as an Additional Director and approved further investments in its subsidiary company.

Exide Industries Ltd reported unaudited financial results for Q2 and H1 FY27, with revenue growth of 18.9% and PAT growth of 46.7%. The company commissioned 6 GWh of Lithium-ion Cell Gigafactory.

Biocon Limited has announced its consolidated financial results for the quarter and half-year ended September 30, 2026, with a 2% YoY increase in consolidated operating revenue to Rs 4,389 crore and a 5% YoY increase in biopharma revenue to Rs 3,583 crore.

Biocon Ltd announced its consolidated financial results for the quarter and half-year ended September 30, 2026, with a 2% YoY increase in consolidated operating revenue to Rs 4,389 crore and a 5% YoY increase in biopharma revenue to Rs 3,583 crore.